CancerDrs

Bladder Cancer clinical trials in Kentucky

12 actively recruiting bladder cancer trials at 11 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
  • Baptist Health Louisville — Louisville, Kentucky
  • UofL Health Medical Center Northeast — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…

Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…

Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in Kentucky:
  • University of Kentucky Chandler Medical Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)

Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in Kentucky:
  • University of Kentucky (UK) - Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in Kentucky:
  • University of Kentucky Chandler Medical Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in Kentucky:
  • University of Kentucky/Markey Cancer Center — Lexington, Kentucky
  • The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
  • UofL Health Medical Center Northeast — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Kentucky:
  • Norton Cancer Institute — Louisville, Kentucky
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
  • Saint Elizabeth Healthcare Fort Thomas — Fort Thomas, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky:
  • Baptist Corbin — Corbin, Kentucky
  • Baptist Hardin — Elizabethtown, Kentucky
  • Baptist Lexington — Lexington, Kentucky
  • Baptist Paducah — Paducah, Kentucky
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25